INTOPIX
intoPIX, leading provider of innovative image processing technologies for professional media applications, is introducing the novel JPEG XS standard with preliminary demonstration of the TICO-XS FPGA and ASIC IP-cores, as well as CPU and GPU SDKs during CES 2019. Promising applications for TICO-XS include self-driving cars, VR/AR gear, displays, smartphones, or any other device that is required to transmit, manage or store video data.
Co-developed by intoPIX’s RD&I team and based on their widely used TICO RDD35 codec, JPEG XS is already generating great interest across various industries such as industrial vision, broadcast, and professional AV. In the future, TICO-XS will be a crucial enabler for technological developments in any video-related device, as it provides the solution for a multitude of problems faced by consumer electronics manufacturers today:
Managing more and better pixels
New resolution formats like
4K and 8K are establishing themselves rapidly. With JPEG XS, high
resolution video can be carried over existing bandwidth, with lossless
quality and imperceptible latency.
Saving cost & power
Utilizing JPEG XS for in-device
video transport reduces internal links and memory. Paired with its
extremely low complexity and low memory use, implementors can
significantly reduce power consumption of any electronic device.
Preserving quality with no latency
Being a line-based
compression technology, JPEG XS induces only a few microseconds of
latency - imperceptible to the human eye. After undergoing rigorous
testing procedures by the ISO JPEG committee, the codec provides fully
transparent quality at compression ratios from as low as 3bpp (8:1) for
graphics, text, movie, gaming content and down to 1,5bpp ~ 16:1
typically for television and natural content.
Simplifying connectivity
Processing video data streams with
JPEG XS generates the crucial bandwidth savings needed to move more
pixels over wired or wireless transmission (Wifi, WiGig, 5G), but also
reduces the need for many internal links within a device.
To display the technology’s capabilities, the Belgian technology provider will present several demos on their CES booth 1129 at Westgate Paradise Center, Las Vegas, NV.
About intoPIX
intoPIX is an innovative technology provider
of compression, image processing, and security solutions to audiovisual
equipment manufacturers. We are passionate about offering people a
higher quality image experience and have developed FPGA/ASIC IP-cores
and software tools that enable leading edge TICO, JPEG XS and JPEG 2000
compression, security, video over IP, and hardware enforcement. More
information on our company, customers, technology and products can be
found on www.intopix.com
.
Follow intoPIX on Twitter @intopix
Relevant imagery can be found on https://www.intopix.com/press-images
Trademarks and registered trademarks are the property of their respective owners. Copyright © 2019 intoPIX SA. All rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190104005431/en/
Contact:
intoPIX Raiffa Lanove, +3210238470 press@intopix.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom